urzine/iStock via Getty Images
- Haemonetics (NYSE:HAE) has announced the sale of its whole blood assets to GVS, S.p.A for up to $67.1M, including $44.6M upfront and potential earn-outs of $22.5M over four years.
- The company intends to use the proceeds from this transaction for general corporate